Pöördumine

FACTS The General Objective of PERCH Despite cervical cancer being the most preventable cancer, it is to contribute to the implementation of Europe’s Beating Cancer Plan, which aims to support Member States’ PERCH PartnERship to is still the 4th most common cancer among women efforts to extend the roll-out of routine HPV vaccination of worldwide and among the girls and boys to eliminate cervical cancer and other top cancers in younger women. cancers caused by HPV in the coming decade. Contrast HPV In 2020, in Europe, there were 58,169 cervical cancer cases and 25,989 deaths. PERCH objectives: Incidence and mortality rates vary widely across Europe, Improve capacities of Member States to plan and with age-standardized incidence rates ranging from less 1. implement HPV vaccination campaigns by sharing 18 European countries and 34 partner than 5 cases per 100,000 women to above 25 cases per 100,000 women and age-standardised mortality rates knowledge and experience. organisations working together to increase from 1 death per 100,000 women to 10 deaths per Improve data and monitoring system on HPV HPV vaccination coverage specially in 2. vaccination and HPV screening. 100,000 women. regions with low coverage and to optimize Source: Global Cancer Observatory (GCO) Improve knowledge and awareness on HPV-related data collection to monitor HPV vaccination 3. disease and prevention in specific target groups coverage and the impact of vaccination. (adolescent girls and boys). HPV vaccination coverages Improve knowledge and abilities for healthcare 4. vary considerably professionals in HPV vaccine communication. Granting authority: European Health and Digital across Europe Executive Agency (HaDEA) under the powers PERCH will contribute to achieve the first objective of the delegated by the European Commission “90-70-90” WHO cervical cancer elimination strategy, of >90% reaching at least 90% of HPV vaccine coverage among girls Project duration: 30 months by the age of 15 years. 1 November 2022 - 30 April 2025 <5% Cervical cancer can be prevented by the HPV vaccination, however HPV vaccination coverages vary considerably 90% 70% 90% of girls of women of women across Europe from less than 5% to more than 90%. fully vaccinated with are screened with a identified with Source: WHO/UNICEF Joint Reporting Form on Immunization (JRF) HPV vaccine by age high-performance cervical disease 15 years. test by 35 years of receive treatment age and again by 45 (90% of women Closing the gap in HPV vaccination coverage across Europe years of age. with precancer treated, and 90% Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not today means closing the gap in unacceptable differences of women with necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them. invasive cancer in the cervical cancer burden across Europe tomorrow. managed). PERCH work packages (WP) 34 partners 18 countries WP1 PERCH PARTNERS Project Management and Coordination: aims to ensure Competent authorities: well-coordinated governance and management of the • Italy (coordinator), Istituto Superiore di Sanità (ISS) Joint Action (JA). • Belgium, Belgian Cancer Centre (SCI) • Croatia, Croatian Institute of Public Health (CIPH) WP2 • Czech Republic, Institute of Health Information and Statistics of the Czech Republic (UZIS) Communication and Dissemination: aims to ensure • Estonia, National Institute for Health Development (NIHD) well coordinated communication in each stage of the • France, French National Cancer Institute (INCa) JA and to maximise the dissemination of the JA’s efforts • Germany, Federal Centre for Health Education (BZgA) and results. • Greece, 1st Regional Heath Authority of Attica (1st YPE) • Hungary, National Public Health Center (NPHC) WP3 • Lithuania, National Public Health Center under The Ministry of Health of the Evaluation: aims to monitor and evaluate the progress Republic of Lithuania (NVSC) of the JA and to assure that the JA accomplishes its • Norway, Norwegian Institute of Public Health (NIPH) • Poland, National Institute of Public Health – Nation Research Institute (NIPH established objectives. NIH – NRI) WP4 • Romania, National Institute of Public Health (INSP)/(NIPH) • Slovak Republic, Ministry of Health of the Slovak Republic (SK MoH) Integration and Sustainability: aims to frame the conditions • Slovenia, Institute of Oncology Ljubljana (IOL) to be fulfilled in order to reach or maintain high HPV • Spain, Institut Català d’Oncologia (ICO) vaccination coverage. • Sweden, Public Health Agency of Sweden (PHAS) WP5 Monitoring: aims to describe how HPV vaccination is Affiliated entities: currently monitored and to propose common data collection • Italy, Università Cattolica del Sacro Cuore (UCSC) • Italy, University of Padova (UNIPD) systems to improve the monitoring of population coverage • Italy, Centro di Riferimento Oncologico di Aviano IRCCS (CRO Aviano) and the impact of HPV vaccination. • Italy, Local Health Authority Research Hospital Reggio Emilia (AUSL RE-IRCCS) WP6 Improving Knowledge and Awareness to Increase • Italy, Interdepartmental Center for Research Ethics and Integrity of National Research Council (CNR - CID Ethics) Contacts: Vaccine Uptake in Target Communities: aims to support • Italy, Oncologic network, prevention and research Institute (ISPRO) Member States to increase knowledge and awareness • Italy, University of Florence (UNIFI) Project management team: on HPV-related disease and prevention in adolescent • Italy, Ministry of Health (IT-MoH) • Estonia, Terviseamet / Health Board (HB) Istituto Superiore di Sanità (ISS), Italy girls and boys. • France, École des hautes études en santé publique (EHESP) Dissemination team: WP7 • Germany, Robert Koch Institute (RKI) Training and Support in Vaccine Communication for • Slovenia, National Institute of Public Health (NIJZ) Institute of Oncology Ljubljana, Slovenia healthcare professionals: aims to provide support to • • Spain, Fundacio Institut d’Investigacio Biomedica de Bellvitge (IDIBELL) Sweden, Karolinska Institutet (KI) [email protected] healthcare professionals in terms of communication Official website: training to facilitate communication with teenagers and Associated partners: www.iss.it/perch their parents about HPV vaccines in order to promote HPV • Ireland, HSE National Immunisation Office (NIO) vaccine confidence. • Greece, Andreas Syggros Hospital for skin and Venereal Diseases (ASH) @HPVprojectPERCH • Greece, Alexandra General Hospital (AH) Saatja: Jaak Jänes <[email protected]> Saadetud: 17.01.2023 12:35 Adressaat: <"SM Info"> Teema: Nõusoleku küsimine osalemaks üleeuroopalises HPV-vaktsineerimise hõlmatust uurivas terviseprojektis Manused: logod.jpg; Project_PERCH_Leaflet.pdf Tere! Kirjutan seoses üleeuroopalise terviseprojektiga, mille eesmärgiks on suurendada inimese papilloomiviiruse (HPV) vaktsiiniga hõlmatust liikmesriikides, et tulevikus esineks vähem HPV poolt põhjustatud haigusi ja pahaloomulisi kasvajaid. Projekti kirjeldav ingliskeelne infoleht on lisatud manusesse. Eestis on HPV poolt põhjustatud haiguste, eriti emakakaelavähi, haigestumus üks kõrgemaid Euroopas ning ilma profülaktilise HPV vaktsineerimiseta ei ole võimalik tulevasi põlvkondi nendest haigustest säästa. Alates 2018. aastast on Eestis pakutud kõigile 12-aastastele tüdrukutele tõhusat ja turvalist 9 kõrge riski HPV tüübi vastu kaitsvat vaktsiini. Meie rõõmuks on umbes 60% tüdrukutest selle pakkumise vastu võtnud. Siiski ei ole 40% tüdrukutest vaktsineeritud ja üks antud projekti eesmärkidest on mõista, mis takistab tüdrukuid ja nende vanemaid andmaks luba seda teha. Küsin antud kirjaga luba lisada Teie organisatsioon Eesti poolsesse huvirühmade (ingl Stakeholder) nimekirja, et vajadusel arutada Teie organisatsiooni poolseid mõtteid ja vaateid sellel teemal. Ajaliselt on Teie sisend minimaalne (võimalikud intervjuud, küsimustikele vastamine jm), kuid Teie poolt saadud info on hindamatu. Loodan väga Teie positiivsele vastusele! Heade soovidega Jaak Jänes projektijuht epidemioloogia ja biostatistika osakond Tervise Arengu Instituut [email protected] www.tai.ee